Technetium tc 99m Apcitide

Technetium Tc-99m Apcitide is a radioconjugate comprised of the small peptide apcitide labeled with the gamma-emitting technetium TC99m (metastable Tc-99).

Online Inquiry

Specification Technical Data Related Products Customer reviews and Q&A Useful Tools Publications

CAT#	10-101-157
CAS	178959-14-3
Background	Technetium Tc 99m (99mTc)-apcitide binds with high affinity and specificity to the glycoprotein IIb/IIIa receptors expressed on activated platelets and, therefore, 99mTc-apcitide scintigraphy should be negative with residual abnormalities caused by old, inactive thrombi and positive with new, active thrombi. Technetium Tc 99m apcitide is indicated for scintigraphic imaging of acute venous thrombosis in the lower extremities in patients with signs and symptoms of acute blood clots. The mechanism of action of technetium Tc 99m apcitide is based on the binding of the small-molecule synthetic peptide, apcitide, to the GPIIb/IIIa receptors on the surface of activated platelets, which are a major component in active thrombus formation.
Synonyms/Alias	Acutect (TN);Technetium Tc 99m apcitide (USP)
M.F/Formula	C51H73N17NaO20S5Tc
M.W/Mr.	1526.45
Application	Technetium Tc 99m apcitide is used for scintigraphic imaging of acute venous thrombosis in the lower extremities in patients with signs and symptoms of acute blood clots.
Activity	Enhancer
Areas of Interest	Thrombosis, deep venous (diagnosis)

CAT#	Product Name	M.W	Molecular Formula	Inquiry
10-101-113	Carbocysteine	179.19	C5H9NO4S	Inquiry
10-101-114	Darifenacin Hydrobromide	507.5	C28H31BrN2O	Inquiry
10-101-115	Deferasirox	373.3615	C21H15N3O4	Inquiry
10-101-135	Carbidopa	226.23 (net); 244.25 (monohydrate)	C10H14N2O4	Inquiry
10-101-74	CCK-4 Acetate	596.71	C29H36N6O6S	Inquiry

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Source#	Synthetic
Storage	-20°C
InChI	InChI=1S/C51H77N17O19S5.Na.O.Tc/c1-26(69)60-24-91-21-33(46(82)56-12-37(72)54-14-39(74)64-32(18-88)45(53)81)66-42(77)17-58-47(83)34(22-92-25-61-27(2)70)65-40(75)15-55-38(73)13-57-49(85)36-20-90-23-43(78)63-30(10-28-4-6-29(71)7-5-28)50(86)67-35(19-89-9-3-8-52)48(84)59-16-41(76)62-31(11-44(79)80)51(87)68-36;;;/h4-7,30-36,71,88H,3,8-25,52H2,1-2H3,(H2,53,81)(H,54,72)(H,55,73)(H,56,82)(H,57,85)(H,58,83)(H,59,84)(H,60,69)(H,61,70)(H,62,76)(H,63,78)(H,64,74)(H,65,75)(H,66,77)(H,67,86)(H,68,87)(H,79,80);;;/q;+1;;+3/p-4/i;;;1+1
InChI Key	GOOAASVKYUERHM-SGNQUONSSA-J
Isomeric SMILES	[H+].CC(=O)NCSCC(C(=O)NCC(=O)NC(CSCNC(=O)C)C(=NCC(=NCC(=NC(C[S-])C(=O)N)[O-])[O-])[O-])NC(=O)CNC(=O)CNC(=O)C1CSCC(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)N1)CC(=O)[O-])CSCCCN)CC2=CC=C(C=C2)O.O=[99Tc+3].[Na+]
References	The affinity of various malignant neoplasms including small cell and non-small cell lung cancer for peptide analogs of somatostatin has been well documented. Depreotide is such an analog and can be complexed with technetium-99m (99mTc depreotide) for optimal imaging properties. Using this radiopharmaceutical, solitary pulmonary nodules (SPN) were previously evaluated in a successful phase II/III trial. The results of the larger multicenter phase III study using 99mTc depreotide to differentiate malignant and benign etiologies in SPN are now presented. A Multicenter Trial with a Somatostatin Analog 99mTc Depreotide in the Evaluation of Solitary Pulmonary Nodules Technetium Tc-99m disofenin cholescintigraphy (CS) and ultrasonography (US) are two major clinical methods used in differentiating biliary atresia (BA) from neonatal jaundice. To compare the diagnostic utility of these two modalities, 66 patients with neonatal cholestasis (15 BA, 3 choledochal cyst (CC), 32 neonatal hepatitis, 13 prolonged jaundice, 2 total parenteral nutrition, and 1 sepsis) underwent Tc-99m disofenin CS and US. The diagnostic sensitivity, specificity, and accuracy of CS in differentiating BA from other forms of neonatal jaundice was 100%, 87.5%, and 90.5%, respectively, and for US 86.7%, 77.1%, and 79.4%, respectively. Tc-99m disofenin CS after premedication with phenobarbital and cholestyramine is a convenient and reliable method of differentiating BA from neonatal hepatitis, with a diagnostic accuracy superior to that of US. However, US is the initial imaging procedure of choice in patients presenting with jaundice to rule out anatomic anomalies such as CC. Comparison technetium of Tc-99m disofenin cholescintigraphy with ultrasonography in the differentiation of biliary atresia from other forms of neonatal jaundice